7. The vaccine composition of claim **6** wherein the BHV-1 glycoprotein is BHV-1 gI glycoprotein having an unglycosylated molecular weight of about 105 kDa and encoded by the nucleotide sequence as depicted in FIG. **5**.

8. The vaccine composition of claim **6** wherein the BHV-1 glycoprotein is BHV-1 gIII glycoprotein having a molecular weight of about 91 kDa and encoded by the nucleotide sequence as depicted in FIG. **6**.

9. The vaccine composition of claim **6** wherein the BHV-1 glycoprotein is BHV-1 gIV glycoprotein having a molecular weight of about 71 kDa and encoded by the nucleotide sequence as depicted in FIG. **7**.

10. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim **6**.

11. A vaccine composition to prevent or ameliorate the symptoms of disease comprising an isolated nucleotide sequence encoding a polypeptide containing at least one protective determinant of a truncated BHV-1 gIV polypeptide operably linked to one or more control sequences such that said isolated nucleotide sequence is expressed in a host cell, wherein said polypeptide consists of residues 1–355 as depicted in FIG. **5**.

12. A method of treating or preventing BHV-1 infection in a bovine host comprising administering to said bovine host a therapeutically effective amount of a vaccine composition according to claim **11**.

* * * * *